We discovered dibenzannulated medium-ring keto lactams
(11,12-dihydro-5H-dibenzo[b,g]azonine-6,13-diones)
as a new antimalarial chemotype. Most of these had chromatographic
LogD7.4 values ranging from <0 to 3 and good kinetic
solubilities (12.5 to >100 μg/mL at pH 6.5). The more polar
compounds in the series (LogD7.4 values of <2) had the
best metabolic stability (CLint values of <50 μL/min/mg
protein in human liver microsomes). Most of the compounds had relatively
low cytotoxicity, with IC50 values >30 μM, and
there
was no correlation between antiplasmodial activity and cytotoxicity.
The four most potent compounds had Plasmodium falciparum IC50 values of 4.2 to 9.4 nM and in vitro selectivity indices of 670 to >12,000. They were more than 4
orders-of-magnitude
less potent against three other protozoal pathogens (Trypanosoma
brucei rhodesiense, Trypanosoma cruzi, and Leishmania donovani) but did have relatively high potency
against Toxoplasma gondii, with IC50 values
ranging from 80 to 200 nM. These keto lactams are converted into their
poorly soluble 4(1H)-quinolone transannular condensation
products in vitro in culture medium and in
vivo in mouse blood. The similar antiplasmodial potencies
of three keto lactam–quinolone pairs suggest that the quinolones
likely contribute to the antimalarial activity of the lactams.